Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dual Roles of Gastric Gland Mucin-specific O-glycans in Prevention of Gastric Cancer.

ABSTRACT: Gastric gland mucin is secreted from gland mucous cells, including pyloric gland cells and mucous neck cells located in the lower layer of the gastric mucosa. These mucins typically contain O-glycans carrying terminal ?1,4-linked N-acetylglucosamine residues (?GlcNAc) attached to the scaffold protein MUC6, and biosynthesis of the O-glycans is catalyzed by the glycosyltransferase, ?1,4-N-acetylglucosaminyltransferase (?4GnT). We previously used expression cloning to isolate cDNA encoding ?4GnT, and then demonstrated that ?GlcNAc functions as natural antibiotic against Helicobacter pylori, a microbe causing various gastric diseases including gastric cancer. More recently, it was shown that ?GlcNAc serves as a tumor suppressor for differentiated-type adenocarcinoma. This review summarizes these findings and identifies dual roles for ?GlcNAc in gastric cancer.

SUBMITTER: Nakayama J

PROVIDER: S-EPMC3972424 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Dual Roles of Gastric Gland Mucin-specific O-glycans in Prevention of Gastric Cancer.

Nakayama Jun J

Acta histochemica et cytochemica 20140218 1

Gastric gland mucin is secreted from gland mucous cells, including pyloric gland cells and mucous neck cells located in the lower layer of the gastric mucosa. These mucins typically contain O-glycans carrying terminal α1,4-linked N-acetylglucosamine residues (αGlcNAc) attached to the scaffold protein MUC6, and biosynthesis of the O-glycans is catalyzed by the glycosyltransferase, α1,4-N-acetylglucosaminyltransferase (α4GnT). We previously used expression cloning to isolate cDNA encoding α4GnT, a ...[more]

PMID: 24761044

Similar Datasets

Decreased Gastric Gland Mucin-specific <i>O</i>-glycans Are Involved in the Progression of Ovarian Primary Mucinous Tumours.

Project description:Ovarian primary mucinous tumours (OPMTs) show an adenoma-borderline-carcinoma sequence with gastrointestinal metaplasia. Gastric gland mucin-specific O-glycans are unique with an α1,4-linked N-acetylglucosamine (αGlcNAc) residue attached to mucin 6 (MUC6). Although αGlcNAc is expected to be expressed in OPMTs, the relationship between αGlcNAc expression and OPMT progression remains unknown. Here, we analysed 104 areas of benign mucinous tumours (benign), 55 areas of borderline mucinous tumours (borderline), and 18 areas of malignant mucinous tumours (malignant) to investigate the expression patterns of αGlcNAc, mucin 2 (MUC2), mucin 5AC (MUC5AC), and MUC6 during the progression of OPMT from benign to malignant. MUC5AC expression was observed in all areas. The frequencies of MUC6- and αGlcNAc-positive areas were decreased with tumour progression. In particular, the decrease in αGlcNAc-positive areas was remarkable. Furthermore, αGlcNAc expression was lower than MUC6 expression at all grades (benign, p < 0.0001; borderline, p = 0.0014; malignant, p = 0.0039). Conversely, there was no difference in the expression frequency or level of MUC2 among the three grades. These results suggest that decreased expression of αGlcNAc relative to MUC6 occurs early in tumour development and marks the initiation of OPMT progression.

| S-EPMC8424251 | biostudies-literature

Structural Diversity of Human Gastric Mucin Glycans.

Project description:The mucin O-glycosylation of 10 individuals with and without gastric disease was examined in depth in order to generate a structural map of human gastric glycosylation. In the stomach, these mucins and their O-glycosylation protect the epithelial surface from the acidic gastric juice and provide the first point of interaction for pathogens such as Helicobacter pylori, reported to cause gastritis, gastric and duodenal ulcers and gastric cancer. The rational of the present study was to map the O-glycosylation that the pathogen may come in contact with. An enormous diversity in glycosylation was found, which varied both between individuals and within mucins from a single individual: mucin glycan chain length ranged from 2-13 residues, each individual carried 34-103 O-glycan structures and in total over 258 structures were identified. The majority of gastric O-glycans were neutral and fucosylated. Blood group I antigens, as well as terminal α1,4-GlcNAc-like and GalNAcβ1-4GlcNAc-like (LacdiNAc-like), were common modifications of human gastric O-glycans. Furthemore, each individual carried 1-14 glycan structures that were unique for that individual. The diversity and alterations in gastric O-glycosylation broaden our understanding of the human gastric O-glycome and its implications for gastric cancer research and emphasize that the high individual variation makes it difficult to identify gastric cancer specific structures. However, despite the low number of individuals, we could verify a higher level of sialylation and sulfation on gastric O-glycans from cancerous tissue than from healthy stomachs.

| S-EPMC5417818 | biostudies-literature

Essential role of gastric gland mucin in preventing gastric cancer in mice.

Project description:Gastric gland mucin secreted from the lower portion of the gastric mucosa contains unique O-linked oligosaccharides (O-glycans) having terminal α1,4-linked N-acetylglucosamine residues (αGlcNAc). Previously, we identified human α1,4-N-acetylglucosaminyltransferase (α4GnT), which is responsible for the O-glycan biosynthesis and characterized αGlcNAc function in suppressing Helicobacter pylori in vitro. In the present study, we engineered A4gnt(-/-) mice to better understand its role in vivo. A4gnt(-/-) mice showed complete lack of αGlcNAc expression in gastric gland mucin. Surprisingly, all the mutant mice developed gastric adenocarcinoma through a hyperplasia-dysplasia-carcinoma sequence in the absence of H. pylori infection. Microarray and quantitative RT-PCR analysis revealed upregulation of genes encoding inflammatory chemokine ligands, proinflammatory cytokines, and growth factors, such as Ccl2, Il-11, and Hgf in the gastric mucosa of A4gnt(-/-) mice. Further supporting an important role for this O-glycan in cancer progression, we also observed significantly reduced αGlcNAc in human gastric adenocarcinoma and adenoma. Our results demonstrate that the absence of αGlcNAc triggers gastric tumorigenesis through inflammation-associated pathways in vivo. Thus, αGlcNAc-terminated gastric mucin plays dual roles in preventing gastric cancer by inhibiting H. pylori infection and also suppressing tumor-promoting inflammation.

| S-EPMC3287219 | biostudies-literature

Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.

Project description:Pancreatic cancer is lethal, as it is often detected late. Thus, novel biomarkers of precursor lesions are needed to devise timely therapies. Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) are major precursors of pancreatic cancer. In normal gastric mucosa, gastric gland mucin-specific O-glycans are unique in having ?1,4-linked N-acetylglucosamine (?GlcNAc) residues attached to MUC6. Recently we reported that ?GlcNAc functions as a tumor suppressor for differentiated-type gastric adenocarcinoma (Karasawa et al., J Clin Invest 122, 923, 2012). MUC6 is also expressed in pancreatic neoplasms, including PanIN and IPMN, but the role of ?GlcNAc expression in pancreatic neoplasms remains unknown. Here, we analyze expression patterns of ?GlcNAc, MUC6 and MUC5AC in pancreatic neoplasms and compare them with progression from PanIN to invasive ductal adenocarcinoma (IDAC) (the PanIN-IDAC sequence; 20 cases) and from IPMN to IPMN with associated invasive carcinoma (IPMNAIC) (the IPMN-IPMNAIC sequence; 20 cases). At both sequences, the frequency of MUC6-positive and ?GlcNAc-positive lesions decreased with tumor progression. We then compared expression levels of ?GlcNAc and MUC6 at each step of the progression. At the PanIN-IDAC sequence, ?GlcNAc expression significantly decreased relative to MUC6 in low-grade PanIN (P = 0.021), high-grade PanIN/intraductal spread of IDAC (P = 0.031) and IDAC (P = 0.013). At the IPMN-IPMNAIC sequence, decreased ?GlcNAc expression was also observed in low-grade IPMN exhibiting gastric-type morphology (P = 0.020). These results suggest that decreased expression of ?GlcNAc relative to MUC6 occurs early and marks the initiation of tumor progression to pancreatic cancer.

| S-EPMC5581519 | biostudies-literature

Essential role of gastric gland mucin in preventing gastric cancer in mice

Project description:To elucidate the molecular mechanism by which A4gnt-null mice develop gastric adenocarcinoma, gastric mucosa was isolated from the stomachs of wild-type and A4gnt-null mice, and microarray analysis was performed. Total RNA was isolated from the gastric mucosa stripped from the muscular layer of the glandular stomach of A4gnt-null and wild-type mice at 5, 10, and 50 weeks of age (one mouse per each group was analyzed).

2011-09-29 | E-GEOD-31074 | biostudies-arrayexpress

Essential role of gastric gland mucin in preventing gastric cancer in mice

2011-09-30 | GSE31074 | GEO

Dual roles of ARID1A in both mucin production and secretion to restrain gastric signet ring cell carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-09-18 | GSE232292 | GEO

Simple sugars to complex disease--mucin-type O-glycans in cancer.

Project description:Mucin-type O-glycans are a class of glycans initiated with N-acetylgalactosamine (GalNAc) ?-linked primarily to Ser/Thr residues within glycoproteins and often extended or branched by sugars or saccharides. Most secretory and membrane-bound proteins receive this modification, which is important in regulating many biological processes. Alterations in mucin-type O-glycans have been described across tumor types and include expression of relatively small-sized, truncated O-glycans and altered terminal structures, both of which are associated with patient prognosis. New discoveries in the identity and expression of tumor-associated O-glycans are providing new avenues for tumor detection and treatment. This chapter describes mucin-type O-glycan biosynthesis, altered mucin-type O-glycans in primary tumors, including mechanisms for structural changes and contributions to the tumor phenotype, and clinical approaches to detect and target altered O-glycans for cancer treatment and management.

| S-EPMC5812724 | biostudies-literature

Dual roles of ARID1A in both mucin production and secretion to restrain gastric signet ring cell carcinoma [Cut & Tag]

Project description:Signet ring cell carcinoma (SRCC) of the stomach is a subtype of gastric cancer with poor prognosis. It is characterized with unique large vacuoles of mucin and compressed nucleus, which resemble signet rings, while the underlying molecular mechanisms driving SRCC remain elusive. Here, we studied whether and how human gastric SRCC-associated ARID1A deficiency drove the disease.

2024-09-18 | GSE232289 | GEO

Dual roles of ARID1A in both mucin production and secretion to restrain gastric signet ring cell carcinoma [RNA-Seq]

2024-09-18 | GSE232288 | GEO